Drug intelligence / Profile preview

ABBV-313

Development stage: Phase 1
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

ABBV-313 is an investigational monoclonal antibody developed by AbbVie, currently in Phase 1 clinical development. It targets the CD40 ligand (CD40L, also known as CD154), a protein primarily expressed on activated T cells that plays a critical role in the costimulatory pathway by binding to CD40 on B cells and other antigen-presenting cells. By inhibiting the CD40L-CD40 interaction, ABBV-313 aims to modulate immune responses and is being explored for the treatment of various autoimmune and inflammatory conditions. Early clinical studies are focused on assessing its safety, pharmacokinetics, and immunogenicity in healthy participants.

Targets

CD40LG (CD40 ligand extracellular domain)

Beyond the preview

Go deeper on ABBV-313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-313.

Explore the full profile